Global Alpha-Emitter Market - Industry Analysis Size Share Growth Trends and Forecast 2024 - 2031

Product Description

The Alpha-Emitter market revenue was xx Million USD in 2019, grew to xx Million USD in 2023, and will reach xx Million USD in 2031, with a CAGR of xx during 2024-2031. Considering the influence of COVID-19 on the global Alpha-Emitter market, this report analyzed the impact from both global and regional perspectives. From production end to consumption end in regions such as North America, Europe, China, and Japan, the report put emphasis on analysis of market under COVID-19 and corresponding response policy in different regions. This report also analyzes the strategies for different companies to deal with the impact of COVID-19 in detail to seek a path to recovery. Under COVID-19 Outbreak, how the Alpha-Emitter Industry will develop is also analyzed in detail in Chapter 1.8 of this report. Major Players in Alpha-Emitter market are: Advanced Accelerator Applications S.A Lantheus Medical Imaging, Inc OrthAlign Z-Medical GmbH + Co. KG Medtronic, plc Cardinal Health, Inc. Zimmer IBA Group Bracco Imaging S.p.A Mallinckrodt plc Zimmer Biomet Holdings, Inc. NTP Radioisotopes SOC Ltd General Electric Co Bayer AG Scopis Most important types of Alpha-Emitter products covered in this report are: Terbium (Tb-149) Astatine (At-211) Bismuth (Bi-212) Actinium (Ac-225) Radium (Ra-223) Lead (Pb-212) Bismuth (Bi -213) Most widely used downstream fields of Alpha-Emitter market covered in this report are: Glioma Melanoma Pancreatic Cancer Ovarian Cancer Thyroid Bone Metastasis Lymphoma Endocrine Tumors Other Medical Applications Major Regions or countries covered in this report: North America Europe China Japan Middle East and Africa South America India South Korea Southeast Asia Others In Chapter 3.4, the report provides analysis of the reasons behind price fluctuations. In chapters 5, 6, and 7, the impact of COVID-19 on the different regions in both production and consumption end and SWOT analysis are pointed out. In Chapters 8, the report presents company's recent development and strategies to deal with the impact of COVID-19.